MedTrace Logo

NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel

NCT00229593 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2014-12-04

No results posted yet for this study

Summary

The purpose of this study is to determine the usefulness of two transdermal gels to be used in the future development for a male contraceptive.

Conditions

  • Contraception

Interventions

DRUG

Nestorone gel

2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment

DRUG

Testosterone Gel

100 mg Testosterone gel daily for 3 weeks

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • University of Washington

    lead OTHER

Principal Investigators

  • William J Bremner, MD, PhD · University of Washington

  • Christina Wang, MD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00229593 on ClinicalTrials.gov